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Abstract
Background: Chest-x-ray is routinely used in the diagnosis of smear negative tuberculosis (TB). This study assesses
the incremental cost per true positive test of a point-of-care digital chest-x-ray, in the diagnosis of pulmonary
mycobacterial infections among HIV patients with presumed tuberculosis undetected by smear microscopy.
Methods: Consecutive patients with clinical suspicion of pulmonary tuberculosis were serially tested for Human
immunodeficiency virus (HIV), their sputum examined for Acid Fast Bacilli then cultured in broth and solid media.
Cultures characterized as tuberculous (M.tb) and non-tuberculous (NTM) mycobacteria by Hain assays were used as
gold standards. A chest-x-ray was classified as: (1) consistent for TB, (2) not consistent for TB and (3) no pathology.
Results: Of the 1391 suspected cases enrolled, complete data were available for 952 (68%): 753/952 (79%) had
negative smear tests while 150/753 (20%) had cultures positive for TB. Of those, 82/150 (55%) had chest-x-ray signs
consistent with TB and 29/82 (35%) were positive for HIV. Within the co-infected, 9/29 (31%) had NTM infections.
Among all suspects, the cost per positive case detected using smear microscopy test was $52.84; the overall
incremental cost per positive case using chest-x-ray in smear negatives was $23.42, and in smear negative, HIV positive
patients the cost was $15.77.
Conclusion: Point-of-care chest-x-ray is a cost-effective diagnostic tool for smear negative HIV positive patients with
pulmonary mycobacterial infection.
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Background
Facilities for confirmation of tuberculosis (TB) using cul-
ture and the newer point-of-care molecular diagnostic
tools are lacking in resource-limited settings. The absence
of a highly sensitive, specific, simple and inexpensive tool
for diagnosis of TB forces care givers in high burden set-
tings to rely mainly on clinical and radiographic indicators
to initiate treatment in smear-negative suspects [1]. Fur-
thermore, since stationary radiographic units are only
available in select hospitals, the vast majority of remotely
located directly observed therapy (DOT) clinics rely on
routine smear microscopy for the diagnosis and treatment
of TB.
Given that non-tuberculous mycobacteria (NTM) tend
to test negative for acid fast bacilli (AFB) on smear mi-
croscopy [2], and the strong association between HIV co-
infection and negative AFB on smear microscopy [3-5],
routine digital chest-x-ray may be a valuable tool for in-
tensified detection of pulmonary TB and NTM diseases in
HIV cases in settings where routine smear microscopy
remains the standard of care for TB diagnosis. In these
settings, HIV infected cases with clinical suspicion of
smear-negative TB are routinely treated for the disease
based on good radiographic signs. Chest-x-ray is the read-
ily available tool for diagnosis of TB in smear-negative
cases in these settings [6-8].
Smear-negative TB in HIV infected cases can be subject
to diagnostic delays or incorrect diagnoses due to the ab-
sence of clinical features of TB which lead to treatment
delays, inappropriate therapies and poor prognoses
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[1,9-11]. Radiographic signs of TB in HIV-infected pa-
tients may vary significantly and can range from the ab-
sence of any radiographic sign to the classical signs
such as cavitation, upper lobe infiltration [12], promin-
ent intra-thoracic lymphadenopathy, miliary shadowing,
pleural effusion, and upper lobe disease [13,14]. The
presence of one or more of the followings: upper lobe
disease, cavity formation, lymphadenopathy with or
without unilateral pleural effusion is reportedly associ-
ated with active TB disease in clinically symptomatic
patients with greater than 80% inter-reader reliability
for each of the listed signs [15].
In this paper, we examined the yield and added cost of
routine digital point-of-care radiographic testing among
HIV-infected patients with pulmonary mycobacterial
infections in a setting with high prevalence of non-
tuberculous mycobacteria using the health care provider’s
perspective over a short time horizon of one year for the
study implementation. While diagnostic accuracy and ac-
ceptability of this algorithm in resource-limited setting
has been described [16], few studies have reported on its
cost-effectiveness.
Methods
New patients with unknown HIV status and a history of
productive cough for at least three weeks were consecu-
tively enrolled at the National TB and Leprosy Training
Center (NTBLTC) in Zaria, Nigeria, from August 2010
through August 2011 as previously reported [2,17]. Writ-
ten informed consents were obtained from the patients.
The study protocol was reviewed and approved by the
Nigerian National Health Research Ethics Committee and
the University of Maryland School of Medicine Institu-
tional Review Board with written expression of support by
the management of the NTBLTC.
HIV status was determined by the standard of care algo-
rithm at the time of the study conduct [18] which con-
sisted of Uni-Gold™ (Trinity Biotech PLC, Co Wicklow,
Ireland) and Determine® HIV-1/2 (Abbott Laboratories.
Abbott Park, Illinois, USA). Chest –x-rays were taken at
enrolment using a portable digital x-ray unit: MinXray
HF120/60HPPWV (MinXray, Inc. Northbrook, Illinois,
USA). This direct radiographic digital imaging unit con-
sists of an X-ray tube, imaging panel, comprehensive
digital applications software, a laptop computer and wire-
less capability for image transmissions. This unit can be
deployed to out-patient clinics, directly observed therapy
(DOT) clinics within, between and outside facilities to
provide radiographic imaging services to patients for a
variety of purposes including surveillance [19].
Three spot sputum samples (a spot sputum sample in
the clinic, then another one collected by the patient in the
morning at home, and a third one the next day in the clinic
[spot-morning-spot]) were collected as part of the standard
of care at the time of the study. Routine direct smear ex-
aminations for acid fast bacilli (AFB) with Ziehl-Neelsen
(ZN) stain were done on the two clinic collected spot sam-
ples and graded as negative if no AFB were seen in at least
100 microscopic fields of any of the two spot samples,
while positive smears were graded as follows: scanty, 1-9
AFB in 100 fields; +1, 10-99 in 100 fields; +2, 1-10 per field
in at least 50 fields; +3, greater than 10 per field in at least
20 fields. The early morning sputum samples, which are
expected to yield high concentrations of mycobacteria,
were then tested per study protocol as follows.
The samples were cultured in the automated BACTEC
MGIT 960™ machine (Becton, Dickinson and Company,
New Jersey, USA). Direct smear examination was not
done on the early morning samples to minimize con-
tamination. Samples without any growth after 42 days of
incubation were removed and classified as negative ac-
cording to the manufacturer’s protocol. Samples with
growth were sub-cultured in blood agar to check for
non-mycobacterial contaminations.
Positive uncontaminated cultures were tested for mem-
bers of Mycobacterium tuberculosis (M.tb) complex
which include: Mycobacterium tuberculosis, africanum,
bovis, canetti, microti etc. These were tested with rapid
TB antigen assay (SD-Bioline Ag MPT64 Rapid™ assay;
Standard Diagnostics, Kyonggi-do, Korea) which identifies
MPT64 antigen specific to members of the M.tb complex
group. The M.tb complex samples were then characterized
with Genotype MTBC test (Hain Lifescience, Nehren,
Germany). Positive cultures with a negative test for M.tb
complex on SD-Bioline were considered NTM isolates and
were sub-cultured on Lowenstein Johnson (LJ) medium.
Cultures with positive growth on LJ were characterized
with Genotype CM/AS assay (Hain Lifescience, Nehren,
Germany) the details of the mycobacteria isolation and
characterization for this study are described elsewhere [2].
Chest-x-ray diagnosis of TB
Patients had chest radiographs taken on site near the
DOT clinic after providing the first spot sputum samples
at the laboratory located near the clinic. All chest-x-rays
were initially scored by a physician trained to read radio-
graphic signs of TB, who was also responsible for the
radiographic diagnosis of TB at the DOT clinic. The
chest-x-rays were then independently scored by a visit-
ing radiologist. Both were blinded to the patients’ smear
microscopy test results. Radiographic signs like bihilar
lymphadenopathy, cavitation, localized discrete opacities,
miliary pattern and pleural effusion were considered
consistent for TB (TB+) while signs like presence of soli-
tary hilar opacity, homogenous opacities in the middle
or lower lung zone, prominent vascular markings were
scored as not consistent for TB (TB±). The absence of
any visible pathologic sign was scored as no pathology.
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Resource cost estimation for smear microscopy and
chest-x-ray
The recurrent costs of the smear and chest-x-ray diagnos-
tic test for TB were calculated by tabulating the ingredi-
ents involved, and their individual costs were determined
by: provider interview, checking the provider’s records,
manufacturer interview, direct price observation and
using WHO-STOP TB planning and budgeting estimates
for Nigeria [20]. In evaluating the cost per test, 25 smears
and 45 chest-x-ray examinations were used as the average
number of tests performed daily. The economic costs of
key capital investments including a MinXray machine
with estimated life span of 15 years and a smear micro-
scope equipment with estimated life span of 10 years were
calculated on annualized bases at a discount rate of 3%
over their estimated life spans using the WHO annualiza-
tion and discount factors tables [21]. The lease value was
used to estimate the cost of the facility used to provide the
services and this was tabulated under the recurrent costs.
The annualized value of capital items was added to the
total costs of recurrent items to get the overall start-up
cost. Costs initially measured in Nigerian Naira were
converted to the US Dollar at the prevalent exchange rate
of $1 =N152 (August, 2011).
Statistical analysis
Measures of accuracy for the smear and chest-x-ray exam-
inations were evaluated using the outcomes of sputum cul-
ture and Hain line probe assay as the gold standard. Kappa
statistics for agreement in the radiographic diagnosis
between the two interpreters were assessed and inter-
preted as previously suggested by Vieira and Garrett [22].
Standard tables of annualization and discount factors were
used to determine the annual cost of capital items. All
statistical analyses were done using statistical analysis
systems (SAS) software (SAS Institute Inc, Cary, North
Carolina, USA).
Cost effectiveness analysis
In evaluating the cost effectiveness, all true culture-positive
mycobacterial infections from smear or chest-x-ray tests
were considered as TB cases. The unit of effectiveness was
the number of TB cases correctly identified by positive
chest-x-ray or smear tests. For the routine smear examin-
ation, the costs of the first and second smear tests were
added then divided by the number of cases correctly iden-
tified on smear test to estimate the cost effectiveness ratio
(CER) (dollars per TB case detected). The cost of chest-x-
ray among the smear-negative suspects was divided by the
number of TB cases among the smear-negatives identified
by chest-x-ray to obtain the incremental cost-effectiveness
ratio (ICER) (additional dollars per case detected). A one
way sensitivity analysis was performed by varying a param-
eter with certain probability distribution: the proportion
of NTM causing pulmonary mycobacterial infections, to
evaluate changes in the ICER following digital chest radio-
graph given that majority were likely to remain undetected
by the routine smear test. We also removed the contribu-
tion of the discounting that accounted for the opportunity
N = 952
HIV+, n = 219
SS+, n = 40
X-ray+, n = 34
CH+ n = 31
CH- n = 3
X-ray-, n = 6
CH+ n = 5
CH- n = 1
SS-, n = 179
X-ray+, n = 54
CH+ n = 29
CH- n = 25
X-ray-, n = 125
CH+ n = 30
CH- n = 95
HIV-, n = 733
SS+, n = 159
X-ray+, n = 141
CH+ n = 122
CH- n = 19
X-ray-, n = 18
CH+ n = 11
CH- n = 7
SS-, n = 574
X-ray+, n = 102
CH+ n = 53
CH- n = 49
X-ray-, n = 472
CH+ n = 38
CH- n = 434
HIV rapid assay               Sputum smear Chest X-ray    Culture/Hain assay (CH)
Figure 1 Summary of results in the study diagnostic pathway among 952 patients with complete test outcomes: n = number of participants
with a test outcome; + = positive outcome; - = negative outcome; SS = sputum smear microscopy test; X-ray = radiographic signs on chest
x-ray taken with MinXray machine; CH = culture (liquid) and Hain assay (line probe assay) for the detection and differentiation of
tuberculous and non-tuberculous mycobacterial species.
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cost to observe the changes in the costs per tests and the
corresponding ICER values.
Results
A total of 1,391 patients were enrolled, with complete test
results available for 952 patients (68.4%) after excluding
contaminated samples from 150 patients (10.8%), and 289
patients (20.8%) who did not have a chest radiograph
taken. Of the 952 patients, 753 (79%) were smear negative
(SS-), 179 (23.8%) of the SS- had co-infection with HIV
(HIV+) and 54 (30.2%) of the HIV + SS- had chest-x-ray
signs that were considered pathologic (abnormal). Among
the SS- patients who were negative for HIV (HIV-), 102
(17.8%) had chest-x-rays that were abnormal. Similarly, 199
of the 952 (20.9%) patients had a positive smear test (SS+)
and within those, 40 (20.1%) were HIV+. In 34 (85%) of the
HIV + SS+ the chest-x-rays were abnormal while among
the SS +HIV- patients, 141 (88.7%) had abnormal chest-x-
ray signs. A summary of outcome by test among the 952
patients included in this analysis is shown in Figure 1.
Of the 952 patients, 319 (34%) had true pulmonary
mycobacterial infections confirmed by culture and mo-
lecular line probe assay and of those, 254 (80%) had M.
tb while the remaining 65 (20%) had NTM infection.
Among the 254 M.tb cases, 91 (36%) were SS-, with 35
(38%) being HIV+, and of those, 30 (86%) had abnormal
chest-x-ray signs, with 20 (67%) having signs consistent
with TB (Table 1). Of the 65 NTM cases identified, 59
(91%) were SS-, with 24 (43%) being HIV+, and of the
SS-HIV+, 18 (75%) had abnormal chest-x-ray signs, with
9 (50%) having signs consistent with TB.
However, among those SS-HIV+ whose chest-x-rays
were not consistent with TB (TB±), 10 (3.9%) actually had
M.tb infections, while 9 (13.9%) had NTM infections.
Overall, among the 753 SS- patients, 150/753 (20%) had
cultures positive for TB. Of those, 82/150 (55%) had
chest-x-ray signs consistent with TB and 29/82 (35%) were
positive for HIV. Within the co-infected, 9/29 (31%) had
NTM infections (Table 1). When the association of HIV
infection with positive chest-x-ray was tested statistically
among the M.tb and NTM separately; HIV+, M.tb cases
were less likely to have x-ray findings consistent with clas-
sical tuberculosis (TB+) compared to HIV-, M.tb cases:
OR =0.47, 95% CI = 0.24-0.91; P = 0.02 and Chi sqr = 5.13.
Similarly, HIV+ NTM cases were less likely to have radio-
graphic findings consistent with the TB+ compared to
HIV-, NTM cases, although this association was not
Table 1 Smear microscopy and chest-x-ray findings




Culture and Hain line probe assays
M.tb NTM Negative
N = 254 N = 65 N = 633
n % n % n %
HIV+ SS+ TB+ 30 11.8 1 1.5 3 0.5
TB± 3 1.2 1 1.5 0 0.0
No pathology 1 0.4 0 0.0 1 0.2
HIV+ SS- TB+ 20 7.9 9 13.9 25 3.9
TB± 10 3.9 9 13.9 78 12.3
No pathology 5 2.0 6 9.2 17 2.7
HIV- SS+ TB+ 119 46.8 3 4.6 19 3.0
TB± 5 2.0 0 0.0 1 0.2
No pathology 5 2.0 1 1.5 6 0.9
HIV- SS- TB+ 38 14.9 15 23.1 49 7.7
TB± 11 4.3 14 21.5 202 31.9
No pathology 7 2.8 6 9.2 232 36.7
M.tb Mycobacterium tuberculosis complex, NTM Non-tuberculous mycobacterium,
SS+ Sputum smear microscopy positive, HIV+ Human immune deficiency virus
positive, HIV- Human immune deficiency virus negative, TB+ Chest-x-ray signs
consistent for TB, TB ± Chest-ray signs not consistent for TB.
Table 2 Sensitivity and specificity of smear microscopy and chest-x-ray for M.tb and NTM by HIV status
HIV positive (n = 219) HIV negative (n = 733)
M.tb (n = 69) NTM (n = 26) M.tb (n = 185) NTM (n = 39)
% (95% CI) % (95% CI) % (95% CI) % (95% CI)
Sputum smear test for all TB suspects Sensitivity 49.3 [42.7-55.9] 7.7 [3.4-12.0] 69.7 [66.4-73.0] 10.3 [7.8-12.8]
Specificity 81.3 [78.6-83.7] 78.7 [75.9-81.2] 90.9 [88.6-92.7] 78.6 [75.9-81.2]
PPV 17.1 [12.5-22.9] 1.0 [0.3-3.6] 64.8 [58.0-71.1] 2.0 [0.8-5.1]
NPV 95.4 [93.6-96.4] 96.8 [95.3-97.9] 92.6 [90.5-94.2] 95.4 [93.6-96.6]
Chest-x-ray for smear-negative TB suspects Net sensitivity 78.3 [72.3-84.3] 42.3 [34.2-50.4] 90.3 [87.9-92.7] 48.7 [44.4-53.0]
Net specificity 65.9 [62.7-68.7] 62.9 [59.7-65.9] 75.5 [72.3-78.4] 63.2 [60.0-66.3]
Net PPV 15.2 [14-16.3] 3.1 [2.6-3.7] 47.0 [45.4-48.6] 5.4 [4.7-6.1]
Net NPV 97.5 [96.1-98.6] 97.5 [97.1-97.8] 97.0 [96.6-97.4] 96.6 [96.1-97.0]
Incremental yield 29.0 [22.4-35.7] 34.6 [26.8-42.4] 20.6 [17.3-23.9] 38.4 [34.2-42.6]
M.tb Mycobacterium tuberculosis complex, NTM Non-tuberculous Mycobacteria, PPV Positive predictive value, NPV Negative predictive value, 95% CI 95% confidence
interval.
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found to be statistically significant: OR= 0.87, 95% CI =
0.32-2.35, P = 0.78 and Chi sqr = 0.08.
The levels of agreements between the two chest-x-ray
readers on the three diagnostic scores were as follows: (1)
consistent with TB (TB+): 82%, kappa = 0.63; (2) not
consistent with TB (TB±): 75% (kappa = 0.50) and no
pathology: 91% (kappa = 0.79).
Sensitivity and specificity of direct smear for M.tb and NTM
Among the HIV+ patients, the sensitivity and specificity
of the direct smear alone for M.tb infection were 49.3%
(95% confidence interval (CI) = 42.7-55.9) and 81.3%
(95% CI = 78.6-83.7). In contrast to M.tb, the sensitivity
of the direct smear for NTM was very low at 7.7% (95%
CI = 3.4-12.0) while the specificity was 78.7 (95% CI =
75.9-81.2). For the HIV- cases, the sensitivity of direct
smear for M.tb and NTM were higher at 69.7% (95% CI =
66.4-73.0) and 10.3% (95% CI = 7.8-12.8) respectively
while the corresponding specificities were: 90.9 (95% CI =
88.6-92.7) and 78.6 (95% CI = 75.9-81.2) (Table 2).
When the outcomes of chest-x-ray were analyzed in se-
quence after the direct smear test for the smear-negatives
Table 3 Estimated cost of ingredients used in the performance of smear microscopy and chest-x-ray diagnostic tests
Diagnostic test Item Unit Unit cost (US dollars) Cost per test Source
Sputum smear (SS) TB Stain Kit (ZN) 250 ml 138.20 2.76 Manufacturer provider’s record
Microscope Piece 1.73 0.03 WHO-Stop TB
Sputum container Piece 0.13 0.13 Provider’s record
Applicator stick 500 Pieces 7.89 0.01 Provider’s record
Immersion oil 500 ml 43.16 0.09 WHO-Stop TB
Slides 50 Pieces 4.28 0.09 WHO-Stop TB
Gloves 100 Pieces 14.47 0.15 WHO-Stop TB
Logbook Piece 3.90 0.02 Provider’s record
Pen 12 Pieces 4.93 0.01 Provider’s record
Lab coat Per day 0.01 <0.01 WHO-Stop TB
Staff salary Per day 28.5 1.14 Interview
Quality control Per day 0.12 <0.01 Provider’s record
Staff training Per day 2.37 0.10 Provider’s record
Building Per day 0.38 0.02 Interview
Electricity Per day 0.75 0.03 Interview
Water Per day 0.30 0.01 Interview
Other Per day 3.50 0.14 Provider’s record
Cost of an SS test 4.73
Chest-x-ray (CXR) MinXray Package 65,000.00 0.46 Manufacturer
Shipment Once 1,500.00 0.01 Manufacturer
Installation and training Once 15,000.00 0.11 Manufacturer
Technical support Per year 2,500.00 0.21 Manufacturer
Apron Piece 100.00 <0.01 Interview
CD-ROM 100 Pieces 0.50 0.50 Observation
Pen 12 Pieces 4.93 0.01 Provider’s record
Logbook Piece 3.90 <0.01 Provider’s record
Staff salary Per day 32.90 0.66 Interview
Building Per day 0.38 <0.01 Interview
Electricity Per day 2.24 0.05 Interview
Quality control Per day 21.58 0.48 Interview
Other Per day 3.00 0.07 Interview
Cost of an CXR 2.56 Oc accounted
2.47 Oc unaccounted
ZN Ziehl Neelsen, Oc Opportunity cost for the capital investment.
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(smear-chest-x-ray algorithm) the sensitivity for NTM in-
fections increased from 7.7% to 42.3% in the HIV+ cases
and from 10.3% to 48.7% among the HIV- cases. Similarly,
the sensitivity for M.tb detection was raised from 49.3% to
78.3% in those with HIV and from 69.7% to 90.3% in those
without HIV infection (Table 2). The positive predictive
values of smear microscopy in HIV positive M.tb and
NTM were 17.1 (95% CI = 12.5 -22.9) and 1.0 (0.3-3.6)
respectively. For the smear-chest-x-ray algorithm, the net
positive predictive values for HIV positive M.tb and NTM
cases were 15.2 (14.0-16.3) and 3.1 (2.6-3.7). The predict-
ive values were generally higher for the HIV negative cases
(Table 2).
Cost per smear and chest-x-ray examination
The cost of ingredients included in the estimation of the
local cost per each test in US dollars is shown in Table 3.
The TB staining kits and staff salary accounted for over
80% of the sputum smear examination cost. For the chest-
x-ray, the main cost drivers were the MinXray digital
imaging unit, the CD-ROMs used in reporting the chest-
x-ray findings, staff salary and quality assurance. Items like
furniture, detergents and all non-accounted costs were
categorized as “other”. The cost of a single sputum smear
examination was higher than a chest-x-ray examination.
Cost-effectiveness ratio (CER) and Incremental
cost-effectiveness ratio (ICER)
Among all subjects, the cost per TB case detected using
an algorithm consisting of two successive sputum smear
microscopy was = $52.84. When the smear tests were
followed by a chest-x-ray in subjects with SS- results
regardless of their HIV status, the incremental cost per
additional case identified was = $23.42. However, the in-
cremental cost decreased to = $15.77 when chest-x-ray
was limited to the SS-HIV+ patients, accounting for the
opportunity cost in the capital items of chest-x-ray ma-
chine and its accessories, and smear microscope. When
the costing was done without the opportunity cost, the
cost per chest-x-ray dropped from $2.56 to $2.47 with
the corresponding changes in the ICER summarized in
Table 4. The cost per smear microscopy test virtually re-
mains unchanged ($4.73 to $4.74) thus no changes in the
CER were seen. When the sensitivity analysis was done by
altering the prevalence of NTM infection among the cases
above and below the 20% findings in this study; the
ICER of the smear-chest-x-ray algorithm decreased with
increase in prevalence and vice-versa. At a low preva-
lence of 5% the ICER = $20.8 for SS-HIV+ (Table 5).
Discussion
The outcome of this study shows that chest-x-ray in
smear-negative TB suspects could significantly improve
the yield of mycobacterial chest infections undetected by
routine smear tests. The previously reported low sensitiv-
ity of smear microscopy test among HIV positive is fur-
ther confirmed by our findings [23,24]. The sensitivity is
lowest in HIV positive cases with NTM infections. How-
ever, the cost for detecting cases among the smear-
negatives with chest-x-ray signs that are consistent for TB
is lowest in those with HIV co-infection. This could be
attributed to the higher than expected yield of radio-
graphic signs among HIV patients with NTM infections
and the numerical differences between HIV infected and
uninfected in which the infected are less. The high yield of
the smear-chest-x-ray algorithm for NTMs among the
smear-negatives means additional cases of the disease with
radiographic signs could be detected at less cost when
compared to the rate at which these cases are initially
diagnosed by smear microscopy alone.
The reports on the performance of smear-chest-x-ray
algorithm in resource-limited settings with a high preva-
lence of HIV show in one study, the algorithm correctly
Table 5 Changes in the incremental cost-effectiveness
ratio (ICER) with changes in the prevalence of pulmonary
NTM infections
Smear negative all Smear negative HIV+
Prevalence NTM TB+ ICER (US $) TB+ ICER (US $)
35% 99 19.45 36 12.7
30% 93 20.70 34 13.5
25% 88 21.90 31 14.8
20% 82 23.50 29 15.8
15% 76 25.36 27 17.0
10% 70 27.54 25 18.3
5% 64 30.12 22 20.8
NTM Non tuberculosis mycobacteria, TB+ smear negative cases with chest-x-ray
signs consistent with tuberculosis.
Table 4 Cost per case detected on SS and incremental
cost-effectiveness ratio (ICER) for additional case
detected on chest-x-ray
Test positive Group TB+
cases
% NTM CER ICER
With Oc Without Oc
Sputum
smear
All 169 3.6 $52.84
Sputum
smear
HIV+ 36 5.6 $57.06
Sputum
smear
HIV- 133 3.0 $51.70
Chest-x-ray SS- 82 29.3 $23.42 $22.68
Chest-x-ray SS-HIV+ 29 31.0 $15.77 $15.25
Chest-x-ray SS-HIV- 53 28.3 $27.67 $25.49
SS- Sputum smear negative, TB+ Tuberculosis positive, NTM Non tuberculous
mycobacteria, HIV+ Human immune deficiency virus positive, CER Cost
effectiveness ratio, Oc Opportunity cost.
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identified more than half of the smear-negative TB-HIV
cases while in another, less than half of the cases are iden-
tified [16,25]. Although GeneXpert MTB/RIF is endorsed
by WHO for routine screening of TB in HIV+ [26,27], the
test however, cannot detect NTMs [28], and given the ob-
served low sensitivity of smear test for the NTMs; chest-
x-ray examination then becomes crucial in settings where
NTM is prevalent and diagnostic test options are limited,
or among those with clinical features of the disease who
test negative on GeneXpert.
Smear-negative TB is a public health concern due to the
attributably high morbidity and mortality in people living
with HIV and acquired immune deficiency syndrome
(AIDS) in resource-limited settings [9,29]. Interestingly,
point-of-care chest-x-ray requires less than half of the re-
sources needed for the initial smear microscopy diagnostic
tests. Although identifying these cases is crucial, treating
them may not be that straightforward since the response
of NTM to conventional TB drugs in this setting is not
known yet.
In this study, false positive cases are identified because
of the culture and molecular line probe assays which are
not part of the standard of care in Nigeria. In practice,
when chest-x-ray is performed on smear-negative pre-
sumed cases of TB, the false-positives also receive treat-
ment for TB. Some have used the initial response to
antibiotics like amoxicillin to differentiate TB from non-
TB pulmonary infections [24,30]. The trade-off between
compromising specificity and positive predictive in favor
of sensitivity comes to play whenever the goal of multiple
diagnostic tests is to maximize disease detection. The cost
implication of treating HIV cases with false-positive TB
has to be taken into consideration when sensitivity is
valued over specificity, since the false positives can be as
many as the true-positives. In HIV patients with presumed
TB, the public health implication of missing a true case of
TB far outweighs the added cost of detecting and treating
a false case of TB. In this study, a cheap second diagnostic
test minimizes false-negative TB by picking all patients
with abnormal chest-x-ray notwithstanding the few HIV
infection cases that may present with a normal chest-x-ray
as our findings show as well as previous reports [10,31].
The HIV co-infected cases also have the tendency to
present with radiographic findings which are not consist-
ent with classical tuberculosis. This is consistent with the
reported findings of Kisembo et al. [32] in which chest
radiographs of HIV negative tuberculosis cases showed
more consolidations and cavities compared to those of
HIV positive tuberculosis cases.
In the absence of a more efficient, cheap and scalable
diagnostic tool for NTM in resource-limited settings,
point-of-care digital chest-x-ray in HIV patients with
smear-negative results may significantly improve diagnosis
and treatment of TB. Given that the machine is portable,
it can be shared between different sites which could fur-
ther lower the cost and improve access to care. The device
operates on portable power generators and is physically
smaller; it requires less space without heavy maintenance
and unlike the conventional stationary X-ray machines it
can fit into different DOT clinic settings. While the initial
capital investment covering the machine cost, shipment,
transportation and installation is significant (about
$81,500 U.S dollars), when spread over the estimated 15
years life time of the machine, we still found its use to be
cost-effective.
Conclusions
In conclusion, the incremental cost of identifying smear
negative HIV positive TB cases with radiographic signs of
tuberculosis using point-of-care digital chest-x-ray is
about 30% of the cost of the initial smear microscopy test.
Given that culture and molecular line probe assays are not
scalable in these settings and GeneX-pert cannot identify
NTM infections, making the point-of-care digital chest-x-
ray routine for smear negatives in all DOT sites will also
enhance detection and treatment of pulmonary non-
tuberculosis mycobacterial infections and maximize the
yield of tuberculosis cases in HIV positive patients.
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